Adma Biologics (ADMA) Debt to Equity (2012 - 2025)

Adma Biologics has reported Debt to Equity for 13 years, with the latest figure at $0.15 in Q4 2025.

• For the quarter ending Q4 2025, Debt to Equity fell 27.08% year-over-year to $0.15; the trailing twelve-month figure through Dec 2025 stood at $0.15 (down 27.08% YoY), and the FY2025 full-year result was $0.15, down 27.08% from the prior year.
• Debt to Equity for Q4 2025 stood at $0.15, down from $0.17 in the prior quarter.
• The five-year high for Debt to Equity was $1.41 in Q3 2022, with the low at $0.15 in Q4 2025.
• Historically, Debt to Equity has averaged $0.73 across 5 years, with a median of $0.85 in 2021.
• Annual changes were most pronounced in 2021 — Debt to Equity jumped 436.23% — and 2024, when it slumped 78.54%.
• Adma Biologics' Debt to Equity stood at $0.67 in 2021, then surged by 39.86% to $0.94 in 2022, then rose by 2.77% to $0.97 in 2023, then tumbled by 78.54% to $0.21 in 2024, then declined by 27.08% to $0.15 in 2025.
• The last three Debt to Equity figures came in at $0.15 (Q4 2025), $0.17 (Q3 2025), and $0.18 (Q2 2025), per Business Quant data.